Sinan Sari1, Zeren Baris, Buket Dalgic. 1. Department of Pediatric Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey. drsinansari@yahoo.com
Abstract
OBJECTIVE: Octreotide has been suggested as a medical treatment option in refractory cases of primary intestinal lymphangiectasia (IL). There are few data about the long-term effect and safety of octreotide for IL in the literature. In the present article we analyzed pediatric cases of primary IL with long-term octreotide treatment and discussed its safety profile. METHODS: Between 1999 and 2008, 13 children were diagnosed in our clinic as having IL. Six patients with primary IL were followed up, receiving octreotide therapy. The clinical data of the patients and duration of therapy, dose, and side effects of octreotide were evaluated. RESULTS: Octreotide, 15 to 20 μg per body weight 2 times daily subcutaneously, was given to all of the patients. Duration of the octreotide treatment changed between 3 and 37 months. Stool frequency decreased in all of the patients after starting octreotide treatment. Serum albumin could be maintained at normal levels in 3 patients. The requirement of albumin infusions decreased in all of the patients. Acute pancreatitis was observed as a side effect of octreotide in 1 patient. CONCLUSIONS: Octreotide may help to maintain serum albumin levels, improve clinical findings, and decrease the requirement of albumin infusions in refractory cases of primary IL.
OBJECTIVE:Octreotide has been suggested as a medical treatment option in refractory cases of primary intestinal lymphangiectasia (IL). There are few data about the long-term effect and safety of octreotide for IL in the literature. In the present article we analyzed pediatric cases of primary IL with long-term octreotide treatment and discussed its safety profile. METHODS: Between 1999 and 2008, 13 children were diagnosed in our clinic as having IL. Six patients with primary IL were followed up, receiving octreotide therapy. The clinical data of the patients and duration of therapy, dose, and side effects of octreotide were evaluated. RESULTS:Octreotide, 15 to 20 μg per body weight 2 times daily subcutaneously, was given to all of the patients. Duration of the octreotide treatment changed between 3 and 37 months. Stool frequency decreased in all of the patients after starting octreotide treatment. Serum albumin could be maintained at normal levels in 3 patients. The requirement of albumin infusions decreased in all of the patients. Acute pancreatitis was observed as a side effect of octreotide in 1 patient. CONCLUSIONS:Octreotide may help to maintain serum albumin levels, improve clinical findings, and decrease the requirement of albumin infusions in refractory cases of primary IL.
Authors: V Salpietro; M Ruggieri; T Alterio; R Mallamace; V Chirico; T Arrigo; C Romano Journal: J Endocrinol Invest Date: 2013-05-22 Impact factor: 4.256
Authors: Ioannis Xinias; Antigoni Mavroudi; Evi Sapountzi; Agathi Thomaidou; Maria Fotoulaki; Athanasios Kalambakas; Elina Karypidou; Konstantinos Kollios; Grigorios Pardalos; George Imvrios Journal: Case Rep Gastroenterol Date: 2013-03-20
Authors: Daniela Testoni; Christoph P Hornik; Megan L Neely; Qinghong Yang; Ann W McMahon; Reese H Clark; P Brian Smith Journal: Early Hum Dev Date: 2015-05-15 Impact factor: 2.699
Authors: Rudolf Huber; Georg Semmler; Alexander Mayr; Felix Offner; Christian Datz Journal: World J Gastroenterol Date: 2020-12-08 Impact factor: 5.742
Authors: Antonella Fattorusso; Elena Sofia Pieri; Giovanni Battista Dell'Isola; Paolo Prontera; Elisabetta Mencaroni; Gabriela Stangoni; Susanna Esposito Journal: Medicine (Baltimore) Date: 2020-07-02 Impact factor: 1.817